Your browser doesn't support javascript.
loading
Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.
Sriskandarajah, Priya; De Haven Brandon, Alexis; MacLeod, Kenneth; Carragher, Neil O; Kirkin, Vladimir; Kaiser, Martin; Whittaker, Steven R.
Afiliação
  • Sriskandarajah P; Division of Cancer Therapeutics, The Institute of Cancer Research, London, SW7 3RP, UK.
  • De Haven Brandon A; The Royal Marsden NHS Foundation Trust, London, UK.
  • MacLeod K; Division of Cancer Therapeutics, The Institute of Cancer Research, London, SW7 3RP, UK.
  • Carragher NO; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK.
  • Kirkin V; Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, UK.
  • Kaiser M; Division of Cancer Therapeutics, The Institute of Cancer Research, London, SW7 3RP, UK.
  • Whittaker SR; The Royal Marsden NHS Foundation Trust, London, UK.
BMC Cancer ; 20(1): 269, 2020 Mar 30.
Article em En | MEDLINE | ID: mdl-32228485
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridonas / Pirimidinonas / Dexametasona / Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Revista: BMC Cancer Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piridonas / Pirimidinonas / Dexametasona / Mieloma Múltiplo / Antineoplásicos Limite: Humans Idioma: En Revista: BMC Cancer Ano de publicação: 2020 Tipo de documento: Article